Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Increased to Buy at StockNews.com
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
Zacks.com on MSN2d
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know
Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close.
MoneyWeek on MSN8d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
BioPharma Dive8d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
The Motley Fool4d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...